ATA 200
Alternative Names: ATA-200; GNT-0007; LGMD-R5/LGMD2C gene therapy - Atamyo TherapeuticsLatest Information Update: 01 Jun 2026
At a glance
- Originator Atamyo Therapeutics
- Class Gene therapies
- Mechanism of Action Gene transference; Sarcoglycan replacements
-
Orphan Drug Status
Yes - Limb girdle muscular dystrophies
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Limb girdle muscular dystrophies
Most Recent Events
- 13 May 2026 Efficacy and pharmacodynamics data from phase I/II clinical trials in Limb girdle muscular dystrophies released by Atamyo Therapeutics
- 09 Mar 2026 Efficacy and adverse events data from a phase Ib/II trial in Limb girdle muscular dystrophy released by Atamyo Therapeutics
- 06 Jun 2025 ATA 200 receives Orphan Drug status for Limb girdle muscular dystrophies in USA